Results 11 to 20 of about 31,394 (214)

Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers.

Journal of the American College of Cardiology, 2022
BACKGROUND Supplements are commonly used by individuals with indications for lipid lowering therapy but evidence of their effectiveness to lower low-density lipoprotein cholesterol (LDL-C) is lacking, particularly when compared with statins.
Luke J Laffin, D. Bruemmer, Michelle Garcia, D. Brennan, E. McErlean, D. Jacoby, E. Michos, P. Ridker, Tracy Y. Wang, K. Watson, H. Hutchinson, S. Nissen   +11 more
semanticscholar   +1 more source

Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases

Cardiovascular Diabetology, 2022
Background Statin treatment increases the risk of new-onset diabetes mellitus (NODM); however, data directly comparing the risk of NODM among individual statins is limited. We compared the risk of NODM between patients using pitavastatin and atorvastatin
W. Seo, S. Seo, Yerim Kim, J. J. Yoo, W. Shin, Jinseob Kim, S. You, Rae Woong Park, Young Min Park, Kyung-Jin Kim, S. Rhee, Meeyoung Park, E. Jin, Sung Eun Kim   +13 more
semanticscholar   +1 more source

Rosuvastatin

Reactions Weekly, 2006
europepmc   +2 more sources

A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics

British Journal of Clinical Pharmacology, 2022
The aim was to comprehensively investigate the effects of genetic variability on the pharmacokinetics of rosuvastatin.
Minna Lehtisalo, S. Taskinen, E. Tarkiainen, M. Neuvonen, J. Viinamäki, M. Paile-Hyvärinen, Tuomas O. Lilius, T. Tapaninen, J. Backman, A. Tornio, M. Niemi   +10 more
semanticscholar   +1 more source

Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights

Drug Design, Development and Therapy, 2022
Cardiovascular disease is one of the leading causes of death around the world with various efforts being made to reduce risk in patients through preventive measures.
Maya R. Chilbert, Dylan C. VanDuyn, S. Salah, C. Clark, Qing Ma   +4 more
semanticscholar   +1 more source

The associations between TMAO-related metabolites and blood lipids and the potential impact of rosuvastatin therapy

Lipids in Health and Disease, 2022
Trimethylamine N-oxide (TMAO)-related metabolites are associated with the pathogenesis of atherosclerotic cardiovascular disease (ASCVD) and are known to disrupt lipid metabolism.
Xiao-quan Xiong, Jian Zhou, Q. Fu, Xiaowei Xu, Shaobin Wei, Sheng-jin Yang, Buxing Chen   +6 more
semanticscholar   +1 more source

The Association between ABCG2 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis

Pharmaceutics, 2022
Although several studies have revealed the association between rosuvastatin pharmacokinetics and the ABCG2 421C>A (rs2231142) polymorphism, most studies were conducted with small sample sizes, making it challenging to apply the findings clinically ...
Yubin Song, H. Lim, Jeong Yee, H. Yoon, H. Gwak   +4 more
semanticscholar   +1 more source

Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study

Stroke, 2022
Background: Atherosclerosis is the leading cause of cardiovascular disease worldwide, including in China. Primary prevention, through lipid-lowering, could avert development of atherosclerosis.
Huaguang Zheng, Hongwei Li, Yilong Wang, Zhan-hui Li, Bo Hu, Xiaogang Li, L. Fu, Hongtao Hu, Zhiyu Nie, Bilian Zhao, Di Wei, B. Karlson, M. Bots, Xiangwen Meng, Yundai Chen, Yongjun Wang   +15 more
semanticscholar   +1 more source

High doses of rosuvastatin induce impaired branched‐chain amino acid catabolism and lead to insulin resistance

Experimental Physiology, 2023
Accumulating evidence indicates that patients treated with rosuvastatin have an increased risk of developing new‐onset diabetes. However, the underlying mechanism remains unclear. In this study, we administered rosuvastatin (10 mg/kg body weight) to male
Xue Bai, Xingzhen Long, Fang Song, Baolin Chen, Changcheng Sheng, Cailin Tang, Li Li, Jiaxing Zhang, Rui Zhang, Jiquan Zhang, Jiali Li   +10 more
doaj   +1 more source

Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers

Frontiers in Nutrition, 2022
Background and Aim Green tea and soy products are extensively consumed in daily life. Research has shown that green tea catechins and soy isoflavones may influence the activity of drug metabolizing enzymes and drug transporters.
Weiwei Zeng, Miao Hu, Hon-Kit Lee, E. Wat, C. Lau, C. Ho, C. Wong, B. Tomlinson   +7 more
semanticscholar   +1 more source